Elucidating the inhibitory role of miR-140-5p in SARS-CoV-2 infection

share:

Brief intro:

  • Author: Xiaoyan Ding, Xiaozhong Chen, Yuheng Liu c d, Jiuxiang He, Yuxin Zhou, Jintao Li a
  • Journal: International Immunopharmacology
  • Publication Date: 2025 Apr 16

Products/Services used in the paper

Request Quote

Abstract

The ongoing COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, has necessitated an urgent need for understanding the molecular mechanisms underlying viral infection and host response. MicroRNAs (miRNAs) have emerged as key regulators in viral pathogenesis, mediating complex interactions between the virus and the host's cellular machinery. In this study, we identify miR-140-5p as a significant factor in the regulation of SARS-CoV-2 entry into host cells. Through comprehensive RNA sequencing analysis of peripheral blood mononuclear cells from COVID-19 patients, we observed significant alterations in the expression of miR-140-5p and its target genes during infection. Further bioinformatics analysis revealed that miR-140-5p targets are predominantly associated with endocytosis-related signaling pathways, suggesting a mechanism by which miR-140-5p may influence SARS-CoV-2 entry. Experimental validation using miR-140-5p mimics demonstrated a significant reduction in viral entry across multiple SARS-CoV-2 variants, confirming the inhibitory role of miR-140-5p on viral replication. These findings suggest that miR-140-5p could potentially be explored as a target for inhibiting viral entry, providing new insights into the role of host miRNAs in SARS-CoV-2 infection and the development of antiviral strategies.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Download